Research Reference
Dihexa
Investigational angiotensin IV analog for synaptogenesis
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Preclinical-Only — For Educational Purposes Only
This compound has no established human dosing. The information below documents preclinical (animal) findings and is provided for research and educational reference only. It is not medical advice or a dosing recommendation.
Dihexa is an investigational angiotensin IV analog studied for cognitive enhancement and synaptogenesis in preclinical models. There is no established human dosing.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 5 mg vial. Resulting concentration: 2.5 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 0.05 mg | 2 units | 0.02 mL | Oral (preclinical — rat)Animal-study derived; no human dose established |
| 0.5 mg | 20 units | 0.2 mL | Oral (preclinical — rat)Higher preclinical range |
| 1 mg | 40 units | 0.4 mL | Oral (preclinical extrapolation)Unvalidated human extrapolation |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Dihexa is an investigational compound with no approved pharmaceutical formulation. Compounded research-peptide forms, when referenced, are supplied as a lyophilized powder in 5 mg or 10 mg vials.
For a 5 mg vial reconstituted with 2 mL of bacteriostatic water, the resulting concentration is 2.5 mg/mL. For a 10 mg vial reconstituted with 2 mL, the concentration is 5 mg/mL. Gently swirl — do not shake — to mix. Store reconstituted vials refrigerated at 2–8°C. No stability data from approved manufacturers exists; handling should follow the compounding source's directions.
No established human reconstitution or dosing protocol exists. The values above describe how a compounded research form is typically prepared, not a validated clinical protocol.
Cycling Protocol
No cycling protocol has been established in humans. Dihexa has only been studied in preclinical (animal) models, and no human clinical trials have been published.
Animal studies describe short-term oral administration over days to weeks for cognitive and synaptogenesis endpoints. No long-term cycling, on/off structure, or maximum duration has been characterized in humans. Any cycling described in community sources is unvalidated extrapolation.
Routes of Administration
Oral (preclinical route): Animal studies administered dihexa orally, as it is designed for oral bioavailability — a distinguishing feature among peptide-derived compounds.
No subcutaneous, intramuscular, or intravenous human route has been characterized in published research. Community sources occasionally describe sublingual or oral use, but these are unvalidated and not supported by human trials.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Cognitive Stack (preclinical) | Dihexa + Cerebrolysin / noopeptic agents | Studied together in cognitive-enhancement preclinical literature | | Synaptogenesis Stack | Dihexa + BPC-157 | Theoretical combined neuroplasticity/repair interest |
No stacking protocols have been validated in humans. Combinations described in community sources are unvalidated extrapolation from preclinical or anecdotal reports.
Side Effects & Safety
- No human safety data — all available information comes from preclinical (animal) studies
- Unknown long-term effects — no chronic human exposure data exists
- Potential cardiovascular effects — as an angiotensin IV analog, interaction with cardiovascular regulation is theoretically possible and uncharacterized in humans
- Unknown reproductive and metabolic effects — not studied in humans
- Lack of regulatory oversight — compounded research forms are not FDA-approved and may vary in purity, potency, and contaminants
Dihexa is investigational and not FDA-approved for any indication. Its use outside authorized research settings is not supported by clinical evidence.
Research Basis
Dihexa (N-hexanoic-Tyr-Ile-(6)aminohexanoic amide) is an analog of angiotensin IV, a peptide fragment of the renin-angiotensin system.
Preclinical findings: Animal studies reported that dihexa potently induced dendritic spine formation and synaptogenesis and improved cognitive performance in rodent models of cognitive impairment (Wright et al., 2015; McCoy et al., 2013). It was described as substantially more potent than BDNF in some synaptogenesis assays.
No human trials: No published human clinical trials have established safety, efficacy, or dosing in humans. The compound remains investigational.
Oral bioavailability: Unlike many peptides, dihexa was designed for oral activity, which is noted in the preclinical literature.
The absence of human data means any dose described in community sources is unvalidated extrapolation from animal studies, not an established clinical protocol.